Cargando…

Novel use of syndromic surveillance to monitor the impact of synthetic cannabinoid control measures on morbidity

BACKGROUND: Using data from syndromic surveillance, the New York City Department of Health and Mental Hygiene (DOHMH) identified an increase in the number of emergency department (ED) visits related to synthetic cannabinoids. Syndromic surveillance data were used to target community-level interventi...

Descripción completa

Detalles Bibliográficos
Autores principales: Nolan, Michelle L., Ehntholt, Amy, Merrill, Thomas, Weiss, Don, Lall, Ramona, Paone, Denise
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613244/
https://www.ncbi.nlm.nih.gov/pubmed/31321202
http://dx.doi.org/10.1186/s40621-019-0210-2
_version_ 1783433016211668992
author Nolan, Michelle L.
Ehntholt, Amy
Merrill, Thomas
Weiss, Don
Lall, Ramona
Paone, Denise
author_facet Nolan, Michelle L.
Ehntholt, Amy
Merrill, Thomas
Weiss, Don
Lall, Ramona
Paone, Denise
author_sort Nolan, Michelle L.
collection PubMed
description BACKGROUND: Using data from syndromic surveillance, the New York City Department of Health and Mental Hygiene (DOHMH) identified an increase in the number of emergency department (ED) visits related to synthetic cannabinoids. Syndromic surveillance data were used to target community-level interventions and assess the real-time impact of control measures in reducing synthetic cannabinoid (“K2”)-related morbidity. METHODS: From April 2015 through September 2015, DOHMH implemented 3 separate interventions to reduce K2-related morbidity by limiting the availability of K2 products. Difference-in-difference analyses compared pre- and post-intervention differences in cannabinoid-related ED visit rates between neighborhoods and controls for Interventions A and B. City-wide count data were used to compare K2-related ED visits before and after Intervention C. RESULTS: Syndromic data showed a reduction in K2-related ED visits following the 3 interventions. Respective decreases in rates of synthetic cannabinoid-related ED visits of 33 and 38% were detected at the neighborhood-level due to Interventions A and B, respectively. A decrease of 29% was calculated at the city level following Intervention C. CONCLUSIONS: In addition to identifying emerging public health concerns, syndromic data can provide valuable real-time evidence on the effectiveness of public health interventions. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40621-019-0210-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6613244
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-66132442019-07-18 Novel use of syndromic surveillance to monitor the impact of synthetic cannabinoid control measures on morbidity Nolan, Michelle L. Ehntholt, Amy Merrill, Thomas Weiss, Don Lall, Ramona Paone, Denise Inj Epidemiol Short Report BACKGROUND: Using data from syndromic surveillance, the New York City Department of Health and Mental Hygiene (DOHMH) identified an increase in the number of emergency department (ED) visits related to synthetic cannabinoids. Syndromic surveillance data were used to target community-level interventions and assess the real-time impact of control measures in reducing synthetic cannabinoid (“K2”)-related morbidity. METHODS: From April 2015 through September 2015, DOHMH implemented 3 separate interventions to reduce K2-related morbidity by limiting the availability of K2 products. Difference-in-difference analyses compared pre- and post-intervention differences in cannabinoid-related ED visit rates between neighborhoods and controls for Interventions A and B. City-wide count data were used to compare K2-related ED visits before and after Intervention C. RESULTS: Syndromic data showed a reduction in K2-related ED visits following the 3 interventions. Respective decreases in rates of synthetic cannabinoid-related ED visits of 33 and 38% were detected at the neighborhood-level due to Interventions A and B, respectively. A decrease of 29% was calculated at the city level following Intervention C. CONCLUSIONS: In addition to identifying emerging public health concerns, syndromic data can provide valuable real-time evidence on the effectiveness of public health interventions. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40621-019-0210-2) contains supplementary material, which is available to authorized users. BioMed Central 2019-07-08 /pmc/articles/PMC6613244/ /pubmed/31321202 http://dx.doi.org/10.1186/s40621-019-0210-2 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Short Report
Nolan, Michelle L.
Ehntholt, Amy
Merrill, Thomas
Weiss, Don
Lall, Ramona
Paone, Denise
Novel use of syndromic surveillance to monitor the impact of synthetic cannabinoid control measures on morbidity
title Novel use of syndromic surveillance to monitor the impact of synthetic cannabinoid control measures on morbidity
title_full Novel use of syndromic surveillance to monitor the impact of synthetic cannabinoid control measures on morbidity
title_fullStr Novel use of syndromic surveillance to monitor the impact of synthetic cannabinoid control measures on morbidity
title_full_unstemmed Novel use of syndromic surveillance to monitor the impact of synthetic cannabinoid control measures on morbidity
title_short Novel use of syndromic surveillance to monitor the impact of synthetic cannabinoid control measures on morbidity
title_sort novel use of syndromic surveillance to monitor the impact of synthetic cannabinoid control measures on morbidity
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613244/
https://www.ncbi.nlm.nih.gov/pubmed/31321202
http://dx.doi.org/10.1186/s40621-019-0210-2
work_keys_str_mv AT nolanmichellel noveluseofsyndromicsurveillancetomonitortheimpactofsyntheticcannabinoidcontrolmeasuresonmorbidity
AT ehntholtamy noveluseofsyndromicsurveillancetomonitortheimpactofsyntheticcannabinoidcontrolmeasuresonmorbidity
AT merrillthomas noveluseofsyndromicsurveillancetomonitortheimpactofsyntheticcannabinoidcontrolmeasuresonmorbidity
AT weissdon noveluseofsyndromicsurveillancetomonitortheimpactofsyntheticcannabinoidcontrolmeasuresonmorbidity
AT lallramona noveluseofsyndromicsurveillancetomonitortheimpactofsyntheticcannabinoidcontrolmeasuresonmorbidity
AT paonedenise noveluseofsyndromicsurveillancetomonitortheimpactofsyntheticcannabinoidcontrolmeasuresonmorbidity